None of the patients had an indication for bradycardia pacing, cardiac resynchronization therapy, ventricular tachycardias with rates <170 beats per minute, or documented monomorphic ventricular tachycardias which could be terminated by antitachycardia pacing. The study protocol of the European Regulatory Trial was approved by the ethics committee at each participating institution. All study participants provided written informed consent.
Device Description
The S-ICD system consists of a pulse generator, which is implanted near the left midaxillary line, and a subcutaneous lead, which is placed 1 to 2 cm parallel to the left midsternal line. The device weighs 145 g and has a volume of 69 mL. The device delivers nonprogrammable 80-J biphasic transthoracic shock and has the capability to provide ventricular bradycardia pacing ≤30 s postshock at a rate of 50 beats per minute. Automatic capacitor reformation is performed 3× per year. Based on this capacitor reformation, the projected longevity of the device is 5 years. Each additional charge reduces longevity by 21 days.
Definition of Device Replacement
Device longevity was defined as the time from implantation to surgical replacement, and thus not necessarily to elective replacement indication (ERI). Reasons for replacement were ERI, premature ERI because of excessive battery drainage, malfunction of device, or infection. Permanent removal of the implanted S-ICD system was defined as explantation. Reasons for explantation were, for example, a change to a transvenous ICD system because of development of an indication for bradycardia pacing, cardiac resynchronization therapy, or antitachycardia pacing. Premature ERI was defined as ERI within 36 months after implantation, which is based on the value given in the warranty. All other replacements based on battery depletion after >36 months service time were defined as normal ERI. End of follow-up with administrative censoring of longevity of devices still in service was set on December 1, 2014.
Data Analysis
Continuous variables are presented as mean±SD or as median with 25th and 75th percentiles, where appropriate. Categorical data are presented as counts and percentages. Event-free rates from device replacement were calculated with the Kaplan-Meier method. Eventfree rates were expressed with a 2-sided 95% confidence interval (CI). Patients who reached the end of follow-up without ERI were censored for administrative reasons. Patients who died before ERI were treated as censored observations. To evaluate the relation between ICD shocks and elective device replacement, Cox regression analysis was applied with number of delivered shocks as time-varying covariate. Statistical analysis was performed using SPSS version 21 (IBM Corp, Somers, NY). Statistical significance was defined as P<0.05 (2-tailed).
Results
Clinical characteristics of the patients enrolled in the European Regulatory Trial are presented in Table. Among the patients, 44 (80%) were men, and 37 (67%) had ischemic heart disease. Primary prevention was the indication for ICD placement in 43 (78%) patients. The number of patients who died before ICD replacement was 8 (15%); 3 cardiac and 5 noncardiac deaths. None of the deaths were related to the S-ICD system or implant procedure.
During a median follow-up of 5.8 years (5.7-5.9 years), 26 (47%) devices were replaced and 5 (9%) were explanted. The indications for device replacement and explantation are presented in Figure 1 . Of the total cohort, 4 (7%) patients had the S-ICD explanted and received a transvenous ICD system. Two of them developed an indication for cardiac resynchronization therapy (CRT) because of symptomatic heart failure (New York Heart Association class III; 0.01 per patient-year), 1 patient had an indication for bradycardia pacing because of symptomatic bradycardia (0.003 per patient-year), and 1 patient received a transvenous ICD system as specified by protocol of the European Regulatory Trial in case of ineffective defibrillation testing. One device was explanted because of infection.
The majority of devices (81%) were replaced based on ERI. Overall, the median time for device replacement was 5.0 years (4.4-5.6 years). Event-free rates for device replacement were 94% (95% CI, 83%-98%) after 2 years, 89% (95% CI,
WHAT IS KNOWN
• The subcutaneous implantable cardioverter defibrillator (ICD) is a viable and safe alternative to contemporary transvenous ICD systems in patients without an indication for bradycardia therapy, cardiac resynchronization therapy, or need for antitachycardia pacing therapy.
WHAT THE STUDY ADDS
• The longevity of the first generation subcutaneous ICD systems is slightly less compared to single-and dual-chamber ICDs.
• Longevity of the subcutaneous ICD is not affected by delivered shock therapy.
• The need for a transvenous ICD system replacement due to the development of an indication for bradycardia therapy, cardiac resynchronization therapy, or antitachycardia pacing therapy is low. 76%-96%) after 4 years, and 30% (95% CI, 15%-46%) after 6 years ( Figure 2 ). However, premature ERI because of rapid battery depletion was observed in 5 devices (9%) with a mean service time of 1.5±0.7 years. Considering the manufacturerprojected device longevity of 5 years, 71% of devices were actually still in service at 5-year follow-up.
We analyzed whether elective device replacement was associated with shock delivery. During follow-up, a total of 119 delivered shocks in 16 individual patients (29%) were recorded. Of these patients, the majority (69%) received fewer than 5 shocks. Proportionally, the occurrence of shock delivery was not different between devices with ERI versus those without ERI (32% versus 27%). The relation between ICD shocks and elective device replacement was further evaluated by Cox regression analysis. Considering the number of shocks as a time-varying covariate in Cox regression analysis, no association between number of shocks and elective device replacement was found (hazard ratio, 1.01; 95% CI, 0.98-1.04; P=0.29).
Discussion
This is the first study to analyze the longevity of the subcutaneous ICD since its clinical introduction. The primary results of this analysis indicate that the median longevity of the S-ICD is 5 years as projected by the manufacturer. The majority of devices were replaced because of battery depletion, and ≈7% of the devices were explanted because of a nonbattery-related indication.
Nowadays, the majority of ICDs are implanted on account of primary prevention of sudden death. The majority of these primary prevention patients are expected to survive their first ICD and will probably need 1 or more device replacements. 16 Device longevity is an important factor to improve the costeffective application of ICD therapy. According to several studies, device longevity increased from a mean of 19 months in the late 1980s to ≈60 months at present. [17] [18] [19] [20] When analyzed per type of contemporary transvenous ICD, single-chamber ICDs have a mean longevity of 5.5 years and dual-chamber ICDs 5.8 years. 20 Compared with contemporary transvenous ICD systems, longevity of the first generation S-ICD is slightly shorter with a median longevity of 5.0 years. During follow-up of the first implanted S-ICD cohort, premature ERI because of rapid battery depletion was observed in 5 devices (9%). Analysis identified a battery manufacturing issue and led to a field safety notification issued at the time of the IDE trial. No adverse clinical outcomes were reported as a result of premature battery ERI, and the replacements were uneventful. In subsequent S-ICD studies, premature battery depletion was observed in 2 cases (0.6%) in the IDE trial and in 1 case (0.2%) in the EFFORTLESS registry. 14, 15 When considering transvenous ICD systems, premature ERI has been reported in 9% of transvenous devices. 21 Battery malfunctions were the most common cause of device failure in a meta-analysis of device registries. 22 A concern with the S-ICD system may be the inability to pace. Obviously, the S-ICD system is not indicated for patients with bradycardia or need for cardiac resynchronization. The number of ICD recipients who require bradycardia pacing during their follow-up is low, 3% of patients in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) and 4% in the Dual Chamber and VVI Implantable Defibrillator (DAVID) study. 3, 23 Heart failure is usually a progressive condition and patients initially implanted with an ICD might later on develop an indication for CRT. The upgrade rate of ICD recipients to CRT varies among studies. In a retrospective single-center study, 3.8% of patients had their device upgraded to CRT during a follow-up of 4 years. 24 Although in the European Cardiac Resynchronization Therapy Survey on CRT implant procedures, 28.2% were identified as upgrade from ICD to CRT-D. 25 In a recent sub study of the Resynchronizationdefibrillation for Ambulatory Heart Failure Trial (RAFT) study, 12.3% of ICD patients had an attempted upgrade to CRT. 26 In our analysis, ≈7% of the S-ICD systems were explanted and replaced by a transvenous ICD system because of the need for bradycardia pacing or CRT. The interim analysis of the EFFORTLESS registry reported a low explant rate of the S-ICD, occurring in 3.7% of patients mainly because of infection. 15 In 1% of patients, the S-ICD was replaced for a transvenous ICD system because of recurrent ventricular arrhythmias or patient decision.
Limitations
There are several limitations to this study. The number of patients is low compared with the IDE trial and the EFFORTLESS registry. However, the median follow-up of the first implanted S-ICD cohort is >5 years warranting an analysis of longevity of the subcutaneous defibrillator. Device longevity was defined as the time from implantation to replacement and thus not the day of detection of ERI. Overestimation of longevity can be neglected because replacement is performed within 1 to 2 weeks after detection of ERI.
Conclusions
The longevity of the first generation S-ICD systems is slightly less compared with single-and dual-chamber ICDs. The majority of devices were replaced because of battery depletion. During a median of 5-year follow-up, the need for a transvenous ICD system replacement was rather low.
Disclosures
Dr Theuns has received institutional grant and consulting fee from Boston Scientific. Dr Hood has received lecture honoraria, institutional grant, and consulting fees from Boston Scientific. Dr Cappato has equity and intellectual property rights from Cameron Health, a subsidiary of Boston Scientific, and lecture honoraria, institutional grant, and consulting fees from Boston Scientific. Dr Knops has institutional grant from Boston Scientific. Dr Maass receives lecture honoraria from Boston Scientific. Dr Boersma receives lecture honoraria and consulting fees from Boston Scientific. The other authors report no conflicts.
